Marc S Raab
University Hospital Heidelberg · Medizinische Klinik V, University Hospital Heidelberg
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Marc S Raab as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:54 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07671287 · GMMG-HD11/DSMM XXI/64007957MMY3010University of Heidelberg Medical Center · not yet recruiting · Multiple Myeloma · principal investigator
- Ph2NCT02834364 · BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)University of Heidelberg Medical Center · completed · Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 11:54 UTC. The ranking covers the 200 most relevant of 47 PubMed records, and a shared surname and initials can bring in a namesake. All 47 on PubMed
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med · 2023617 citationsRCR 54.5
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.N Engl J Med · 2018436 citationsRCR 14.4
- 294 citationsRCR 8.1
- 227 citationsRCR 6.7
- Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.Leukemia · 2008171 citationsRCR 3.6
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.Leukemia · 2018167 citationsRCR 5.9
- 161 citationsRCR 11.2
- Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.Lancet Haematol · 2015135 citationsRCR 4.0
- 114 citationsRCR 3.7